tetano
Editor, Senior Moderator
Vaccine
Available online 16 February 2012
Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines
Ralf D. Hessa, Corresponding author contact information, E-mail the corresponding author,
Friedemann Weberb, c,
Keith Watsond,
Siegfried Schmittdd
a PAREXEL Consulting, Kartaeuser-Str. 47, 79102 Freiburg, Germany
b Institute for Virology, Philipps-University Marburg, D-35043 Marburg, Germany
c Centre for Biological Signalling Studies (BIOSS), Albert-Ludwigs-Universit?t, Freiburg, Germany
d PAREXEL Consulting, The Quays, 101-105 Oxford Road, Uxbridge, Middlesex UB8 1LZ, United Kingdom
Received 10 November 2011. Revised 31 January 2012. Accepted 5 February 2012. Available online 16 February 2012.
http://dx.doi.org/10.1016/j.vaccine.2012.02.015, How to Cite or Link Using DOI
Permissions & Reprints
Abstract
In the development of novel substrates used for production of human vaccines there has been significant progress made in recent years. Emerging and re-emerging infectious diseases like the recent porcine Influenza A virus (H1N1) pandemic necessitated the availability of unprecedented amounts of vaccines. In addition, the high demand for vaccines in the industrialised countries has also been paralleled by a steep increase in demand in developing countries.
The manufacturing capability for viral vaccines produced in embryonated hen eggs and conventional/classical cell substrates, such as chicken embryo fibroblasts, has now reached its capacity limit. This constraint may be overcome by utilising other recognised cell substrates such as Madin Darby Canine Kidney (MDCK) (dog origin), Chinese Hamster Ovary (CHO) (hamster cells) or Vero cells (monkey origin) or as an alternative, introduce new cell substrates of human or avian origin. Using new cell substrates may prove to be a highly replication-proficient way of producing live viral vaccines such as Influenza A viruses. Despite some advantages, cell substrates may pose a small residual risk to humans since some of them are known to be tumourigenic in immunosuppressed animals. However, this residual risk should be considered acceptable by regulators. Safety testing requirements for cell substrates used in the manufacture of vaccines is mandated by published guidance from organisations such as World Health Organization (WHO), United States Food and Drug Administration (FDA), European Medicines Agency (EMA) and International Conferences on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use (ICH) as well as requirements laid down in compendial monographs (Ph. Eur. and USP). This paper considers the guidance contained in these regulatory documents. In addition, the safety challenges and almost arbitrary risk-based classification of cell substrates used in the production of human vaccines together with compliance to GCCP (Good Cell Culture Practice) are discussed. Even though there has been tremendous progress in the last few years, reflected mainly by revisions and updates to regulatory guidance documents, there still is still no consensus between regulators nor significant harmonisation of the guidance documents or monographs.
Highlights
► Up-to-date regulatory requirements for cell substrate characterisation. ► Comprehensive information from different regulatory frameworks (WHO, EU/EP, USA/FDA and ICH). ► Focus on the manufacture of live attenuated viral vaccines and its problems associated with downstream purification. ► Focus on major concerns such as tumourigenicity and oncogenicity of PCC. ► Arbitrary risk based classification of cell substrates for the manufacture of vaccines for human use.
http://www.sciencedirect.com/science/article/pii/S0264410X12001806
Available online 16 February 2012
Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines
Ralf D. Hessa, Corresponding author contact information, E-mail the corresponding author,
Friedemann Weberb, c,
Keith Watsond,
Siegfried Schmittdd
a PAREXEL Consulting, Kartaeuser-Str. 47, 79102 Freiburg, Germany
b Institute for Virology, Philipps-University Marburg, D-35043 Marburg, Germany
c Centre for Biological Signalling Studies (BIOSS), Albert-Ludwigs-Universit?t, Freiburg, Germany
d PAREXEL Consulting, The Quays, 101-105 Oxford Road, Uxbridge, Middlesex UB8 1LZ, United Kingdom
Received 10 November 2011. Revised 31 January 2012. Accepted 5 February 2012. Available online 16 February 2012.
http://dx.doi.org/10.1016/j.vaccine.2012.02.015, How to Cite or Link Using DOI
Permissions & Reprints
Abstract
In the development of novel substrates used for production of human vaccines there has been significant progress made in recent years. Emerging and re-emerging infectious diseases like the recent porcine Influenza A virus (H1N1) pandemic necessitated the availability of unprecedented amounts of vaccines. In addition, the high demand for vaccines in the industrialised countries has also been paralleled by a steep increase in demand in developing countries.
The manufacturing capability for viral vaccines produced in embryonated hen eggs and conventional/classical cell substrates, such as chicken embryo fibroblasts, has now reached its capacity limit. This constraint may be overcome by utilising other recognised cell substrates such as Madin Darby Canine Kidney (MDCK) (dog origin), Chinese Hamster Ovary (CHO) (hamster cells) or Vero cells (monkey origin) or as an alternative, introduce new cell substrates of human or avian origin. Using new cell substrates may prove to be a highly replication-proficient way of producing live viral vaccines such as Influenza A viruses. Despite some advantages, cell substrates may pose a small residual risk to humans since some of them are known to be tumourigenic in immunosuppressed animals. However, this residual risk should be considered acceptable by regulators. Safety testing requirements for cell substrates used in the manufacture of vaccines is mandated by published guidance from organisations such as World Health Organization (WHO), United States Food and Drug Administration (FDA), European Medicines Agency (EMA) and International Conferences on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use (ICH) as well as requirements laid down in compendial monographs (Ph. Eur. and USP). This paper considers the guidance contained in these regulatory documents. In addition, the safety challenges and almost arbitrary risk-based classification of cell substrates used in the production of human vaccines together with compliance to GCCP (Good Cell Culture Practice) are discussed. Even though there has been tremendous progress in the last few years, reflected mainly by revisions and updates to regulatory guidance documents, there still is still no consensus between regulators nor significant harmonisation of the guidance documents or monographs.
Highlights
► Up-to-date regulatory requirements for cell substrate characterisation. ► Comprehensive information from different regulatory frameworks (WHO, EU/EP, USA/FDA and ICH). ► Focus on the manufacture of live attenuated viral vaccines and its problems associated with downstream purification. ► Focus on major concerns such as tumourigenicity and oncogenicity of PCC. ► Arbitrary risk based classification of cell substrates for the manufacture of vaccines for human use.
http://www.sciencedirect.com/science/article/pii/S0264410X12001806